Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes

American Journal of Pathology

Volumn 169, Issue 4, 2006, Pages 1183-1193

  Feldon, Steven E ^a   O'Loughlin, Charles W ^a   Ray, Denise M ^a   Landskroner Eiger, Shira ^a   Seweryniak, Kathryn E ^a   Phipps, Richard P ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA 12,14 PROSTAGLANDIN J2; CIGLITAZONE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN J2; UNCLASSIFIED DRUG; 15 DEOXYPROSTAGLANDIN J2; 15-DEOXYPROSTAGLANDIN J2; DRUG DERIVATIVE; LIGAND; MEMBRANE PROTEIN; PTGS2 PROTEIN, HUMAN;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; FIBROBLAST; GRAVES DISEASE; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; BIOSYNTHESIS; COCULTURE; CYTOLOGY; DRUG POTENTIATION; ENZYMOLOGY; METABOLISM; ORBIT;

ADIPOCYTES; ADIPOGENESIS; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; CYCLOOXYGENASE 2; FIBROBLASTS; GRAVES DISEASE; HUMANS; LIGANDS; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; ORBIT; PPAR GAMMA; PROSTAGLANDIN D2; PROSTAGLANDINS; T-LYMPHOCYTES;

EID: 34447516158     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.060434     Document Type: Article

References (50)

1. Smith RS, Smith TJ, Blieden TM, Phipps RP: Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997, 151:317-322
2. Gabbiani G: The myofibroblast: a key cell for wound healing and fibrocontractive diseases. Prog Clin Biol Res 1981, 54:183-194
3. Phan SH: The myofibroblast in pulmonary fibrosis. Chest 2002, 122:286S-289S
4. Brody JS, Kaplan NB: Proliferation of alveolar interstitial cells during postnatal lung growth. Evidence for two distinct populations of pulmonary fibroblasts. Am Rev Respir Dis 1983, 127:763-770
5. Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP: Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol 2003, 163:1291-1300
6. Maksvytis HJ, Niles RM, Simanovsky L, Minassian IA, Richardson LL, Hamosh M, Hamosh P, Brody JS: In vitro characteristics of the lipid-filled interstitial cell associated with postnatal lung growth: evidence for fibroblast heterogeneity. J Cell Physiol 1984, 118:113-123
7. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR-γ). J Biol Chem 1995, 270:12953-12956
8. 2 is a ligand for the adipocyte determination factor PPAR-γ. Cell 1995, 83:803-812
9. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995, 83:813-819
10. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, Lazar MA, Chatterjee VK: A dominant-negative peroxisome proliferator-activated receptorγ (PPAR-γ) mutant is a constitutive repressor and inhibits PPAR-γ-mediated adipogenesis. J Biol Chem 2000, 275:5754-5759
11. Tamori Y, Masugi J, Nishino N, Kasuga M: Role of peroxisome proliferator-activated receptor-γ in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 2002, 51:2045-2055
12. Zhang J, Fu M, Cui T, Xiong C, Xu K, Zhong W, Xiao Y, Floyd D, Liang J, Li E, Song Q, Chen YE: Selective disruption of PPAR-γ2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci USA 2004, 101:10703-10708
13. Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, Sorisky A: Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2002, 87:385-392
14. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106:679-684
15. Aniszewski JP, Valyasevi RW, Bahn RS: Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab 2000, 85:776-780
16. Kahaly G, Hansen C, Felke B, Dienes HP: Immunohistochemical staining of retrobulbar adipose tissue in Graves' ophthalmopathy. Clin Immunol Immunopathol 1994, 73:53-62
17. Weetman AP, Cohen S, Gatter KC, Fells P, Shine B: Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 1989, 75:222-227
18. Trokel SL, Jakobiec FA: Correlation of CT scanning and pathologic features of ophthalmic Graves' disease. Ophthalmology 1981, 88:553-564
19. Pappa A, Lawson JM, Calder V, Fells P, Lightman S: T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy. Br J Ophthalmol 2000, 84:517-522
20. Smith TJ, Sempowski GD, Wang HS, Del Vecchio PJ, Lippe SD, Phipps RP: Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts. J Clin Endocrinol Metab 1995, 80:2620-2625
21. Fries KM, Sempowski GD, Gaspari AA, Blieden T, Looney RJ, Phipps RP: CD40 expression by human fibroblasts. Clin Immunol Immunopathol 1995, 77:42-51
22. Feldon SE, Park DJ, O'Loughlin CW, Nguyen VT, Landskroner-Eiger S, Chang D, Thatcher TH, Phipps RP: Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. Invest Ophthalmol Vis Sci 2005, 46:3913-3921
23. Qiu Z, Wei Y, Chen N, Jiang M, Wu J, Liao K: DNA synthesis and mitotic clonal expansion is not a required step for 3T3-L1 preadipocyte differentiation into adipocytes. J Biol Chem 2001, 276:11988-11995
24. Darimont C, Avanti O, Zbinden I, Leone-Vautravers P, Mansourian R, Giusti V, Mace K: Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes. Biochimie 2006, 88:309-318
25. Shahparaki A, Grunder L, Sorisky A: Comparison of human abdominal subcutaneous versus omental preadipocyte differentiation in primary culture. Metabolism 2002, 51:1211-1215
26. Giusti V, Verdumo C, Suter M, Gaillard RC, Burckhardt P, Pralong F: Expression of peroxisome proliferator-activated receptor-γ1 and peroxisome proliferator-activated receptor-γ2 in visceral and subcutaneous adipose tissue of obese women. Diabetes 2003, 52:1673-1676
27. 2 metabolite generated during inflammatory processes. J Biol Chem 2002, 277:10459-10466
28. Jiang C, Ting AT, Seed B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86
29. Rosen ED: The transcriptional basis of adipocyte development. Prostaglandins Leukot Essent Fatty Acids 2005, 73:31-34
30. Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP, Smith TJ: Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem 1998, 273:29615-29625
31. Iniguez MA, Punzon C, Fresno M: Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol 1999, 163:111-119
32. Pablos JL, Santiago B, Carreira PE, Galindo M, Gomez-Reino JJ: Cyclooxygenase-1 and -2 are expressed by human T cells. Clin Exp Immunol 1999, 115:86-90
33. Xu L, Zhang L, Yi Y, Kang HK, Datta SK: Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 2004, 10:411-415
34. 2 and the ligation of PPAR-γ. J Clin Invest 2003, 112:945-955
35. 2 and related compounds: an update. Prostaglandins Leukot Essent Fatty Acids 1992, 47:1-12
36. 2. Identification of products formed in vitro. J Biol Chem 1983, 258:11713-11718
37. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG: Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res 2005, 65:6189-6198
38. 2-derived activators of peroxisome proliferator-activated receptor-γ are formed in macrophage cell cultures. Biochim Biophys Acta 2003, 1631:35-41
39. Prabhakar BS, Bahn RS, Smith TJ: Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 2003, 24:802-835
40. Sorisky A, Pardasani D, Gagnon A, Smith TJ: Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab 1996, 81:3428-3431
41. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM: PPAR-γ is required for placental, cardiac, and adipose tissue development. Mol Cell 1999, 4:585-595
42. 2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 1982, 129:1627-1631
43. Levin F, Kazim M, Smith TJ, Marcovici E: Rosiglitazone-induced proptosis. Arch Ophthalmol 2005, 123:119-121
44. Starkey K, Heufelder A, Baker G, Joba W, Evans M, Davies S, Ludgate M: Peroxisome proliferator-activated receptor-γ in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab 2003, 88:55-59
45. 2, and peroxisome proliferator activated receptor-gamma agonists induce apoptosis in transformed, but not normal, human T lineage cells. Immunology 2002, 105:23-34
46. 2 induces IL-8 production in human T cells by a mitogen-activated protein kinase pathway. J Immunol 2002, 168:1372-1379
47. 2 induce apoptosis in normal and malignant B-lineage cells. J Immunol 2000, 165:6941-6948
48. Padilla J, Leung E, Phipps RP: Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists. Clin Immunol 2002, 103:22-33
49. - subpopulations exhibit distinct phenotypes. Eur J Immunol 2002, 32:477-485
50. Sempowski GD, Rozenblit J, Smith TJ, Phipps RP: Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol 1998, 274:C707-C714